Neuroprotection in subarachnoid hemorrhage.
Despite advances in aneurysm ablation and the initial management of patients presenting with aneurysmal subarachnoid hemorrhage, delayed cerebral ischemia remains a significant source of morbidity. Traditionally, delayed cerebral ischemia was thought to be a result of vasospasm of the proximal intracranial vessels, and clinical trials have relied largely on radiographic evidence of vasospasm as a surrogate for functional outcome. However, a number of trials have demonstrated a dissociation between angiographic vasospasm and outcome, and more recent data suggest that other mechanisms of injury, such as microvascular dysfunction and complex neuronal-glial interactions, may influence the development of delayed ischemic deficit after aneurysmal subarachnoid hemorrhage. Our evolving understanding of the pathophysiology of delayed cerebral ischemia may offer the opportunity to test new therapeutic strategies in this area and improve clinical trial design.
Laskowitz
Daniel T
DT
Departments of Medicine Neurology, Duke University, Durham NC 27710, USA. danl@neuro.duke.edu
Kolls
Brad J
BJ
D001921:Brain / Q000098:blood supply; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy*; D020301:Vasospasm, Intracranial / Q000188:drug therapy*
D018696:Neuroprotective Agents